ClinicalTrials.gg
RecruitingNCT07055165Updated Sep 25, 2025

Connect2Care: Prostate Cancer Education and Screenings for African American Men

An interventional study of Prostate Cancer Genius App and US Prevention Taskforce App in Prostate Cancer and Health Behavior, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to male participants aged 45 Years to 69 Years. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by University of Oklahoma · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
466
Allocation
Randomized
Ages
45 Years to 69 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
262nd of 3,024
466 · median 48
Started
2025
with 160 others
No phase
764 of 3,597
157 open now
Primary completion
2026-12
later than 229 of 968 live
Registered
3,377th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 262nd largest by planned enrollment of the 3,024 interventional ones that give a count, is one of 161 that started in 2025, is one of 764 with no phase, reaches primary completion later than 229 of the 968 other live ones, and was the 3,377th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 45 Years to 69 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Prostate cancer is the most diagnosed cancer in African American men and the second-leading cause of cancer-related death. The prostate-specific antigen (PSA) test is an early detection screening tool for prostate cancer, however, knowledge about prostate cancer and screening benefits and risks and uptake of PSA screening remains low among African American men. To address this inequity, this project proposes the use of the Connect2Care App to improve knowledge of prostate cancer, screening benefits, risks and increase readiness to complete a PSA test (e.g., intentions, motivation, confidence, and self-efficacy). The primary goal of this study is to evaluate the efficacy of the Connect2Care App in a 30-day randomized control trial compared to an existing app developed by the U.S. Department of Health \& Human Services (Prevention Taskforce App). African American men between the ages of 45 and 69 from Oklahoma (N = 266), who are not up to date with PSA screening according to recommended guidelines, will be randomly assigned 1:1 to receive either app. The app feasibility will be assessed: (1) efficacy, evaluated via post-intervention differences in knowledge of prostate cancer, screening benefits and risks, (2) app engagement and accessibility, measured via self-report validated questionnaires, and (3) app acceptability, explored via semi-structured qualitative interviews. We will explore readiness to complete a PSA test and identify predictors of readiness across both study arms. The successful demonstration of the feasibility of the Connect2Care App among African American men living in Oklahoma will support expanding this intervention to African American men nationwide.

Read the detailed description

Prostate cancer is the most diagnosed cancer in African American men and the second-leading cause of cancer-related death. The prostate-specific antigen (PSA) test is an early detection screening tool for prostate cancer, however, knowledge about prostate cancer and screening benefits and risks and uptake of PSA screening remains low among African American men. To address this inequity, this project proposes the use of the Connect2Care App to improve knowledge of prostate cancer, screening benefits, risks and increase readiness to complete a PSA test (e.g., intentions, motivation, confidence, and self-efficacy). The primary goal of this study is to evaluate the efficacy of the Connect2Care App in a 30-day randomized control trial compared to an existing app developed by the U.S. Department of Health \& Human Services (Prevention Taskforce App). African American men between the ages of 45 and 69 from Oklahoma (N = 266), who are not up to date with PSA screening according to recommended guidelines, will be randomly assigned 1:1 to receive either app. The app feasibility will be assessed: (1) efficacy, evaluated via post-intervention differences in knowledge of prostate cancer, screening benefits and risks, (2) app engagement and accessibility, measured via self-report validated questionnaires, and (3) app acceptability, explored via semi-structured qualitative interviews. We will explore readiness to complete a PSA test and identify predictors of readiness across both study arms. The successful demonstration of the feasibility of the Connect2Care App among African American men living in Oklahoma will support expanding this intervention to African American men nationwide.

A. Specific Aims

The overall objectives of this proposal are to: (1) address two key SDOH (i.e., neighborhood and built environment and access to high-quality preventive care); (2) leverage community and individual levels of influence; and (3) implement a social risk screener and social needs referral process, at both community and individual levels, that mitigates significant barriers to PSA screening and timely follow-up care. Our central hypothesis is that combining a traditional community-engaged research intervention with an innovative smartphone app navigation intervention, while providing access to free PSA screening tests and follow-up care at Stephenson Cancer Center (see Letter of Support), will have a meaningful impact on prostate cancer outcomes among AA men in Oklahoma. This hypothesis has been formulated based on our promising pilot data (see Preliminary Studies). To attain our overall objectives, we will recruit a total of 466 AA men, aged 55-69 and not up to date with PSA screening. As such, the following specific aims are proposed:

Aim 1. Conduct a multimodal community outreach intervention to improve awareness of and access to PSA screening. Approach. The intervention will include (1) a culturally tailored Social Media Campaign, geofenced to counties with the greatest AA prostate cancer incidence. Participants who click on the campaign can order a free at-home PSA test. (2) In-person Community Health Events will provide educational information and access to on-site PSA screening via our mobile screening vans. A total of 200 AA men will be accrued across both outreach methods. Outcomes. Awareness will be measured by the reach and penetration of the interventions and access by the number of completed PSA screening tests.

Aim 2. Determine the efficacy of smartphone intervention on at-home PSA screening rates. Approach. A total of 266 AA men will be randomized to a two-arm RCT for 4 weeks. Intervention arms include US Preventive Services Task Force App (control) vs. Prostate Cancer Genius App (Genius App; intervention). In both arms, participants will receive information about prostate cancer and screening, have access to a free at-home PSA test and free follow-up care, and social needs referrals. Participants in the Genius App will also have access to several culturally tailored, novel features to support at-home PSA screening. Outcomes. Efficacy (primary outcome) is determined by PSA screening rates 30 days post-randomization.

Aim 3. Explore the feasibility and acceptability of a social risk screening tool to connect participants to social needs referral services. Approach. After completing a baseline social risk screener, all participants will receive some form of navigation for social needs referral. Navigation will differ by type and intensity. Participants accrued by community outreach will receive One-Time Navigation via a list of referral resources, tailored to their social needs assessment and geography. Participants enrolled in the smartphone intervention will receive Weekly Navigation, which provides more intensive support via a study navigator and geofenced social needs notifications on their study app. Outcomes. Feasibility will be measured by the percentage of participants who complete a social risk screener, and the percentage connected to a referral service. Acceptability will be assessed via qualitative exit interviews (N=80), stratified by social need (high vs. low).

03

Conditions studied

  • Prostate Cancer
  • Health Behavior
04

Who can participate

Ages eligible
45 Years to 69 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Live in Oklahoma
  • Self-identify as Black/African American
  • Self-identify as male
  • Between ages 45-69
  • Not currently diagnosed with prostate cancer

Exclusion criteria

Exclusion Criteria:

  • Participants will be excluded if they are not interested in using a phone app for 30 days
  • Has taken a PSA test or has completed PSA screening within the past two years
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
466 participants (estimated)

Study arms

  • Experimental
    Genius app

    The Prostate Cancer Genius app includes the following components: (1) educational content that is consistent with existing evidence and recommendations for prostate cancer and prostate cancer screening but has been adapted for the African American male population and for adults who read at or below the 8th-grade level; (2) real-time messages about the risks of prostate cancer and the benefits of completing a PSA test, placing a special emphasis on screening considerations for individuals with a family history of prostate cancer and/or lower urinary tract symptoms (measured via the American Urological Association Symptom Score); (3) general trivia that also incorporates quiz questions about prostate cancer and the PSA test; (4) African American-specific testimonials and educational videos; (5) optional counseling by African American prostate cancer survivors; and (6) on-demand, automated ordering of a home-based PSA test.

    Behavioral: Prostate Cancer Genius App

  • Active comparator
    Prevention Taskforce app

    The Prevention Taskforce app provides on-demand access to evidence-based recommendations for prostate cancer for men between 55 and 69 (i.e., it can be accessed as needed).

    Behavioral: US Prevention Taskforce App

Interventions

  • BehavioralProstate Cancer Genius App

    Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.

  • BehavioralUS Prevention Taskforce App

    Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.

06

What researchers measure

Primary outcomes

  1. Awareness

    Awareness will be measured by reach and penetration of the intervention. For the Social Media Campaign, reach will be determined by the percentage of participants who successfully engage with intervention and will be calculated by the number of impressions (i.e., number of times adverts are seen) divided by the number of times participants engaged with the intervention (i.e., click through rate). This will determine a click through rate, which can be calculated per study ad and geographic region. For the Community Health Events, reach will be determined by the number of events hosted and the number of participants who attend. Penetration will also be explored through a geographic informational systems (GIS) analysis to better understand whether spatial (e.g., distance to CHCO sites) and/or participant-level characteristics (e.g., age) were associated with greater likelihood to engage with the intervention (both Social Media Campaign and Community Health Events) and/or complete a PSA.

    Time frame: 30 Days

Secondary outcomes

  1. Access

    Access will be measured by the number of PSA tests completed. The pre- and post-test surveys will assess sociodemographic characteristics, knowledge, attitudes and beliefs about prostate cancer and readiness to screen

    Time frame: 30 Days

07

Study locations

1 of 1 sites recruiting
  • TSET Health Promotion Research Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
    • Jan Foisy · Contact
    • Jordan Neil, PhD · Principal investigator
    • Adam Alexander, PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 17 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2025
First posted
Jul 8, 2025
StartActual
Jul 26, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07055165
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Jul 26, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 25, 2025

Study contacts

Jordan Neil, PhD
Contact
jordan-neil@ouhsc.edu
(405) 271-5046
Adam Alexander, PhD
Contact
adam-alexander@ouhsc.edu
(405) 271-5046
Jordan Neil, PhD
principal investigator · University of Oklahoma

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion